tramól-l forðatafla 100 mg
teva b.v.* - tramadolum hýdróklóríð - forðatafla - 100 mg
tramól-l forðatafla 150 mg
teva b.v.* - tramadolum hýdróklóríð - forðatafla - 150 mg
tramól-l forðatafla 200 mg
teva b.v.* - tramadolum hýdróklóríð - forðatafla - 200 mg
xtandi
astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
lumeblue (previously known as methylthioninium chloride cosmo)
alfasigma s.p.a. - metýlþíóníumklóríð - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.
fem-mono retard forðatafla 60 mg
viatris limited - isosorbidi mononitras inn - forðatafla - 60 mg